Noninvasive Prognostic Models, Imaging, and Elastography to Predict Clinical Events in Primary Sclerosing Cholangitis: A Review

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2023 Oct 30

PMID 37900215

Authors

Mark W Russo

Affiliations

Soon will be listed here.

Abstract

Surrogate endpoints are needed to estimate clinical outcomes in primary sclerosing cholangitis (PSC). Serum alkaline phosphatase was among the first markers studied, but there is substantial variability in alkaline phosphatase levels during the natural history of PSC without intervention. The Mayo risk score incorporates noninvasive variables and has served as a surrogate endpoint for survival for more than two decades. Newer models have better test performance than the Mayo risk score, including the primary sclerosing risk estimate tool (PREsTo) model and UK-PSC score that estimate hepatic decompensation and transplant free survival, respectively. The c-statistics for transplant-free survival for the Mayo risk model and the long-term UK-PSC model are 0.68 and 0.85, respectively. The c-statistics for hepatic decompensation for the Mayo risk model and PREsTo model are 0.85 and 0.90, respectively. The Amsterdam-Oxford model included patients with large duct and small duct PSC and patients with PSC-autoimmune hepatitis overlap and had a c-statistic of 0.68 for transplant-free survival. Other noninvasive tests that warrant further validation include magnetic resonance imaging, elastography and the enhanced liver fibrosis score. Prognostic models, noninvasive tests or a combination of these surrogate endpoints may not only serve to be useful in clinical trials of investigational agents, but also serve to inform our patients about their prognosis.

References

Cazzagon N, Lemoinne S, El Mouhadi S, Trivedi P, Gaouar F, Kemgang A . The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. Am J Gastroenterol. 2019; 114(12):1878-1885. DOI: 10.14309/ajg.0000000000000461. View

Bakhshi Z, Hilscher M, Gores G, Harmsen W, Viehman J, LaRusso N . An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. J Gastroenterol. 2020; 55(5):523-532. PMC: 8157157. DOI: 10.1007/s00535-020-01663-1. View

Lopens S, Wunsch E, Milkiewicz M, Rober N, Zarske G, Nasser A . PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis. Diagnostics (Basel). 2022; 12(11). PMC: 9689935. DOI: 10.3390/diagnostics12112682. View

Lindstrom L, Hultcrantz R, Boberg K, Friis-Liby I, Bergquist A . Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013; 11(7):841-6. DOI: 10.1016/j.cgh.2012.12.032. View

Vesterhus M, Hov J, Holm A, Schrumpf E, Nygard S, Godang K . Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015; 62(1):188-97. DOI: 10.1002/hep.27825. View

de Vries E, Beuers U, Ponsioen C . Biomarkers for disease progression of primary sclerosing cholangitis. Curr Opin Gastroenterol. 2015; 31(3):239-46. DOI: 10.1097/MOG.0000000000000163. View

Arndtz K, Corrigan M, Rowe A, Kirkham A, Barton D, Fox R . Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. BMJ Open. 2017; 7(6):e015081. PMC: 5734279. DOI: 10.1136/bmjopen-2016-015081. View

Hirschfield G, Chazouilleres O, Drenth J, Thorburn D, Harrison S, Landis C . Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2018; 70(3):483-493. DOI: 10.1016/j.jhep.2018.10.035. View

Ponsioen C, Chapman R, Chazouilleres O, Hirschfield G, Karlsen T, Lohse A . Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology. 2015; 63(4):1357-67. DOI: 10.1002/hep.28256. View

10.

Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouilleres O, Arrive L . Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology. 2013; 59(1):242-50. DOI: 10.1002/hep.26620. View

11.

Stanich P, Bjornsson E, Gossard A, Enders F, Jorgensen R, Lindor K . Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011; 43(4):309-13. PMC: 3057302. DOI: 10.1016/j.dld.2010.12.008. View

12.

Saffioti F, Roccarina D, Vesterhus M, Hov J, Rosenberg W, Pinzani M . Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. Eur J Clin Invest. 2019; 49(5):e13088. DOI: 10.1111/eci.13088. View

13.

Mamari S, Djordjevic J, Halliday J, Chapman R . Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2012; 58(2):329-34. DOI: 10.1016/j.jhep.2012.10.013. View

14.

Kim W, Therneau T, Wiesner R, Poterucha J, Benson J, Malinchoc M . A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000; 75(7):688-94. DOI: 10.4065/75.7.688. View

15.

Wiesner R, Grambsch P, Dickson E, Ludwig J, MacCarty R, Hunter E . Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989; 10(4):430-6. DOI: 10.1002/hep.1840100406. View

16.

De Vries E, Wang J, Williamson K, Leeflang M, Boonstra K, Weersma R . A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut. 2017; 67(10):1864-1869. PMC: 6145288. DOI: 10.1136/gutjnl-2016-313681. View

17.

Ghonem N, Auclair A, Hemme C, Gallucci G, de la Rosa Rodriguez R, Boyer J . Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clin Pharmacol Ther. 2020; 108(6):1213-1223. PMC: 7886378. DOI: 10.1002/cpt.1930. View

18.

Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A . Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996; 38(4):610-5. PMC: 1383124. DOI: 10.1136/gut.38.4.610. View

19.

Dhillon A, Kummen M, Troseid M, Akra S, Liaskou E, Moum B . Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. Liver Int. 2018; 39(2):371-381. DOI: 10.1111/liv.13979. View

20.

Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou M, Azizi Z . A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. J Gastrointestin Liver Dis. 2016; 25(4):457-464. DOI: 10.15403/jgld.2014.1121.254.rah. View